Adma Biologics, Inc.
ADMA· Nasdaq
Released Mar 3, 2025, after the close
10-K filed Mar 18, 2025, 77 days after period end · 0001140361-25-009257
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $117.55M | $73.90M | $49.98M | $26.38M |
| Net Income | $111.90M |
Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR
| -$17.64M |
| -$12.23M |
| -$16.65M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.